Patents by Inventor Anil M. Kumar
Anil M. Kumar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11922220Abstract: Embodiments of systems, apparatuses and methods provide enhanced function as a service (FaaS) to users, e.g., computer developers and cloud service providers (CSPs). A computing system configured to provide such enhanced FaaS service include one or more controls architectural subsystems, software and orchestration subsystems, network and storage subsystems, and security subsystems. The computing system executes functions in response to events triggered by the users in an execution environment provided by the architectural subsystems, which represent an abstraction of execution management and shield the users from the burden of managing the execution. The software and orchestration subsystems allocate computing resources for the function execution by intelligently spinning up and down containers for function code with decreased instantiation latency and increased execution scalability while maintaining secured execution.Type: GrantFiled: April 16, 2019Date of Patent: March 5, 2024Assignee: Intel CorporationInventors: Mohammad R. Haghighat, Kshitij Doshi, Andrew J. Herdrich, Anup Mohan, Ravishankar R. Iyer, Mingqiu Sun, Krishna Bhuyan, Teck Joo Goh, Mohan J. Kumar, Michael Prinke, Michael Lemay, Leeor Peled, Jr-Shian Tsai, David M. Durham, Jeffrey D. Chamberlain, Vadim A. Sukhomlinov, Eric J. Dahlen, Sara Baghsorkhi, Harshad Sane, Areg Melik-Adamyan, Ravi Sahita, Dmitry Yurievich Babokin, Ian M. Steiner, Alexander Bachmutsky, Anil Rao, Mingwei Zhang, Nilesh K. Jain, Amin Firoozshahian, Baiju V. Patel, Wenyong Huang, Yeluri Raghuram
-
Patent number: 7618968Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor cells.Type: GrantFiled: August 6, 2007Date of Patent: November 17, 2009Assignee: Cell Therapeutics, Inc.Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A Jenkins, J Peter Klein, Anil M Kumar, John Tulinsky
-
Patent number: 7399860Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.Type: GrantFiled: April 2, 2003Date of Patent: July 15, 2008Assignee: Cell Therapeutics Inc.Inventors: Anil M. Kumar, J. Peter Klein, Rama Bhatt, Edward Vawter
-
Patent number: 7291616Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity and/or proliferation of cells such as tumor cells.Type: GrantFiled: October 30, 2002Date of Patent: November 6, 2007Assignee: Cell Therapeutics, Inc.Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A. Jenkins, J. Peter Klein, Anil M. Kumar, John Tulinsky
-
Patent number: 7053096Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.Type: GrantFiled: May 5, 2004Date of Patent: May 30, 2006Assignee: Cell Therapeutics Inc.Inventors: David Porubek, Anil M. Kumar, Charles R. Bredl, J. Peter Klein
-
Patent number: 6878715Abstract: Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S.Type: GrantFiled: April 7, 2000Date of Patent: April 12, 2005Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Stephen J. Klaus, Anil M. Kumar, Baoqing Gong
-
Publication number: 20040229836Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.Type: ApplicationFiled: May 5, 2004Publication date: November 18, 2004Applicant: CELL THERAPEUTICS, INC.Inventors: David Porubek, Anil M. Kumar, Charles R. Bredl, J. Peter Klein
-
Patent number: 6780865Abstract: Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.Type: GrantFiled: September 18, 1997Date of Patent: August 24, 2004Assignee: Cell Therapeutics, Inc.Inventors: David Porubek, Anil M. Kumar, Charles R. Bredl, J. Peter Klein
-
Patent number: 6774130Abstract: Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S.Type: GrantFiled: April 9, 1999Date of Patent: August 10, 2004Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Stephen J. Klaus, Anil M. Kumar, Baoqing Gong
-
Patent number: 6693105Abstract: Disclosed are therapeutic compounds having the formula: (R)j—(CORE MOIETY), including resolved enantiomers, diastereomers, hydrates, salts, solvates or mixtures thereof where j is an integer from one to three. The core moiety is a bicyclic ring structure having at least one heterocyclic ring that contains five to six ring atoms and up to two nitrogen heteroatoms. R is selected from the group consisting of hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted benzyl, C1-6 alkyl or C1-6 alkenyl, and at least one R has the formula I: n is an integer from 1 to 20, at least one of X or Y is —OH. Another of X or Y, which is not —OH, is hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2—or (CH3)2—CH2—, and each W1, W2, and W3 is independently hydrogen, CH3—, CH3—CH2—, CH3—(CH2)2— or (CH3)2—CH2—.Type: GrantFiled: July 27, 1999Date of Patent: February 17, 2004Assignee: Cell Therapeutics, Inc.Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
-
Publication number: 20040002526Abstract: The invention is directed to thiazolidinones and the use thereof to inhibit phospholipase D (PLD) activity. The invention further relates to methods of treating cancer and inflammatory diseases using thiazolidinones.Type: ApplicationFiled: April 1, 2003Publication date: January 1, 2004Applicant: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Anil M. Kumar, Marc J. McKennon
-
Publication number: 20030224971Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.Type: ApplicationFiled: April 2, 2003Publication date: December 4, 2003Applicant: CELL THERAPEUTICS, INC.Inventors: Anil M. Kumar, J. Peter Klein, Rama Bhatt, Edward Vawter
-
Publication number: 20030207901Abstract: Disclosed are therapeutic compounds having the formula:Type: ApplicationFiled: May 14, 2003Publication date: November 6, 2003Applicant: Cell Therapeutics, Inc.Inventors: Gail E. Underiner, David Porubek, J. Peter Klein, Paul Woodson, Stephen J. Klaus, Anil M. Kumar, John Tulinsky
-
Publication number: 20030153570Abstract: The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase &bgr; (LPAAT-&bgr;) activity and/or proliferation of cells such as tumor cells.Type: ApplicationFiled: October 30, 2002Publication date: August 14, 2003Applicant: Cell Therapeutics, Inc.Inventors: Rama Bhatt, Baoqing Gong, Feng Hong, Scott A. Jenkins, J. Peter Klein, Anil M. Kumar, John Tulinsky
-
Patent number: 6469017Abstract: A method for blocking IL-12 signaling by administration of the following compound: wherein, R1 is H, CH3, sulfate, phosphate, or salt thereof; R2 is alkyl (C1-12), alkoxyalkyl (C1-11), dialkoxyalkyl, CH2C6H5, —CH2-furan, biotin; and R3 is H, CH3 or CH2C6H5.Type: GrantFiled: January 16, 1998Date of Patent: October 22, 2002Assignee: Cell Therapeutics, Inc.Inventors: Stephen J. Klaus, J. Peter Klein, Anil M. Kumar
-
Publication number: 20020077279Abstract: The invention provides new processes for preparing polyglutamic acid-therapeutic agent conjugates for clinical development and pharmaceutical use, and polyglutamic acid-therapeutic agent conjugates prepared by these processes.Type: ApplicationFiled: October 9, 2001Publication date: June 20, 2002Inventors: Anil M. Kumar, J. Peter Klein, Rama Bhatt, Edward Vawter
-
Publication number: 20020028823Abstract: Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g.Type: ApplicationFiled: April 9, 1999Publication date: March 7, 2002Inventors: J. PETER KLEIN, STEPHEN J. KLAUS, ANIL M. KUMAR, BAOQING GONG
-
Patent number: 6103730Abstract: Compounds and pharmaceutical compositions, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, have the formula:CORE MOIETY--(R).sub.jIn these compounds, j is an integer from one to three; the core moiety is a cyclic core, the cyclic core being non-cyclic or at least one five- to seven-member non-heterocyclic ring or heterocycle; and R is selected from the group consisting of amine, hydrogen, halogen, hydroxyl, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic group or formula I. At least one R having formula I: ##STR1## In formula I, n is an integer from four to twenty; and each R.sub.1 or R.sub.2 is independently hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or cyclic or heterocyclic group.Type: GrantFiled: June 7, 1995Date of Patent: August 15, 2000Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Gail E. Underiner, Anil M. Kumar, Lance H. Ridgers
-
Patent number: 6100271Abstract: Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula:CORE MOIETY --(R).sub.jwherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R may be selected from among hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(2-10) alkenyl, carbocyclic or heterocyclic groups and at least one R has the formula I: ##STR1## wherein: one or two p are the integer one, otherwise p is two; and n is an integer from three to twenty; R.sub.1 is selected from the group consisting of substituted and unsubstituted CH.sub.2 ; NR.sub.3, R.sub.3 being hydrogen, substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl or C.sub.(1-20) hydroxyalkyl, or carbocyclic or heterocyclic group; O; --CHR.sub.4 O--, R.sub.4 being substituted or unsubstituted C.sub.(1-20) alkyl, C.sub.(1-20) alkoxyl, C.sub.(2-20) alkenyl, C.sub.(1-20) hydroxyalkyl, or R.sub.Type: GrantFiled: June 7, 1995Date of Patent: August 8, 2000Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Alistair J. Leigh, Gail E. Underiner, Anil M. Kumar
-
Patent number: 6075029Abstract: A new class of xanthine compounds, variously substituted at the 1, 3, 7 and 8 positions, is characterized by an ability to modulate the activity of key enzymes involved in drug metabolism. These compounds generally are useful in affecting drug metabolism and, particularly, in extending the circulating half-life of compounds that are metabolized via P-450-mediated pathways.Type: GrantFiled: January 2, 1998Date of Patent: June 13, 2000Assignee: Cell Therapeutics, Inc.Inventors: J. Peter Klein, Anil M. Kumar, Paul Woodson